Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Accumulated Depreciation (2016 - 2024)

Historic Accumulated Depreciation for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Q4 2024 value amounting to $419000.0.

  • Syndax Pharmaceuticals' Accumulated Depreciation rose 194.65% to $419000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $419000.0, marking a year-over-year increase of 194.65%. This contributed to the annual value of $419000.0 for FY2024, which is 194.65% up from last year.
  • As of Q4 2024, Syndax Pharmaceuticals' Accumulated Depreciation stood at $419000.0, which was up 194.65% from $411000.0 recorded in Q4 2023.
  • Syndax Pharmaceuticals' 5-year Accumulated Depreciation high stood at $443000.0 for Q4 2021, and its period low was $399000.0 during Q4 2020.
  • In the last 5 years, Syndax Pharmaceuticals' Accumulated Depreciation had a median value of $411000.0 in 2023 and averaged $414200.0.
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Accumulated Depreciation soared by 2870.97% in 2020, and later plummeted by 993.23% in 2022.
  • Quarter analysis of 5 years shows Syndax Pharmaceuticals' Accumulated Depreciation stood at $399000.0 in 2020, then rose by 11.03% to $443000.0 in 2021, then decreased by 9.93% to $399000.0 in 2022, then grew by 3.01% to $411000.0 in 2023, then rose by 1.95% to $419000.0 in 2024.
  • Its Accumulated Depreciation was $419000.0 in Q4 2024, compared to $411000.0 in Q4 2023 and $399000.0 in Q4 2022.